mp.weixin.qq.com·· 12 hours agoPickScore86
Phase 3 TELIGAN Trial Reports 104-Week eGFR Slope and Proteinuria Results for Telitacicept in IgA Nephropathy
In brief
The TELIGAN trial presented final 104-week results for telitacicept in IgA nephropathy at the 2026 American Society of Nephrology (ASN) annual meeting. The study enrolled 318 patients in China.
Why it matters
Week-104 eGFR slope, proteinuria remission, renal progression events and safety all had placebo controls for direct comparison of long-term efficacy and risk.
Source: mp.weixin.qq.com · mp.weixin.qq.com